Stewart AG, Laupland KB, Edwards F, Chen SC.A, Slavin MA. Differences in clinical outcomes among patients with mold fungemia. Open Forum Infect Dis. 2025;13(1):ofaf793. doi: 10.1093/ofid/ofaf793.
Australian and New Zealand Study Group for Non-Aspergillus Mold Infections. Current epidemiology and infection characteristics of non-Aspergillus mold infections: A multicenter study in Australia and New Zealand. Clin Infect Dis. 2026. Advance online publication. doi: 10.1093/cid/ciag029.
Liu AJ, Batterham E, Nedumannil R, Ritchie D, Wei AH, Bajel A, Slavin MA, Yong MK. Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia. Leuk Lymphoma. 2025. doi: 10.1080/10428194.2025.2599991.
Sastre-Escolà E, Yong MK, Tio SY, Douglas A, Morrissey CO, Reynolds G, Chee L, Bajel A, Rex JH, Slavin M, Neoh CF. Rhino-sino-orbital and/or central nervous system infections due to Lomentospora prolificans and Scedosporium spp. in onco-haematology patients. Med Mycol. 2026 Feb 20:myag016. doi: 10.1093/mmy/myag016. Online ahead of print. PMID: 41718671.
MacPhail A, Loke J, Houston BL, Dendle C, Henden AS, Weinkove R, Morrissey O, Neofytos D, Buetti N, Parker C, Slavin MA, Craddock C, Stanworth SJ, McQuilten Z; Australasian Leukaemia and Lymphoma Group Supportive Care Working Group and UK AML/Supportive Care Working Parties. Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice. Br J Haematol. 2026 Feb 12. doi: 10.1111/bjh.70358. Online ahead of print. PMID: 41677362.
Desoubeaux G, Mikulska M, Lemaignen A, Gyan E, Stemler J, Vanbiervliet Y, Maertens J, Lortholary O, Paccoud O, Slavin MA, Cornely OA, Neofytos D, Lanternier F. Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis: duration of therapy in invasive aspergillosis. Clin Microbiol Infect. 2026 Feb 7:S1198-743X(26)00054-6. doi: 10.1016/j.cmi.2026.01.030. Online ahead of print. PMID: 41662953.
Martin‑Loeches I, Cornely OA, Denning DW, Guinea J, Bassetti M, Maertens J, Hoenigl M, Kanj SS, Slavin M, Ostrosky‑Zeichner L, Muñoz P. Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy. Intensive Care Med. 2025. PMID: 41117944.
Neoh CF, Yong MK, Rowley L, Roberts AW, Kennedy GA, He S, Schwarer AP, Bilmon IA, Wei AH, Slavin MA. Antifungal prophylaxis in patients with FLT3‑ITD‑positive acute myeloid leukaemia receiving sorafenib during induction and consolidation (ALLG AMLM16 trial). J Antimicrob Chemother. 2025. PMID: 41133432.
Khanina A, Singh N, Wen J, Chen C, James R, Kong DCM, Slavin MA, Thursky KA. Antifungal use and appropriateness: a study of Australian Hospital National Antimicrobial Prescribing Survey data. Antimicrob Steward Healthc Epidemiol. 2025. PMID: 41306699.
Yeoh DK, Butters C, Clark JE, Slavin MA, McMullan BJ, Haeusler GM, Blyth CC. Invasive mould infection in children – advances made or obstacles remaining? Clin Microbiol Infect. 2025. PMID: 41317867.
Reynolds GK, Slavin MA. Reporting infections in cellular therapies. Blood Adv. 2025 Dec. PMID: 41325091.
Liu, A.J., Batterham, E., Nedumannil, R., Ritchie, D., Wei, A.H., Bajel, A., Slavin, M.A., Yong, M.K. Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia. Leuk Lymphoma. 2025. doi: 10.1080/10428194.2025.2599991
Garg P, Yong KY, Khanina A, Yong MK, Hall L, Slavin MA, Smibert O, Worth LJ. Infection Prevention and Surveillance in the Care of Australasian Solid‑Organ Transplant Recipients. Transpl Infect Dis. 2025. PMID: 41364068.
Tio, S.Y., C.F. Neoh, D. Ritchie, L. Chee, D.C.M. Kong, L.J. Worth, M.K. Yong, and M.A. Slavin. The Changing Epidemiology of Breakthrough Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the Era of Modified-Release Posaconazole Prophylaxis. Transpl Infect Dis. 2025.
Mikulska, M., C. Robin, D. Neofytos, C. Oltolini, A. Piekarska, E. Reigadas, L. Gil, R.F. Chemaly, A.H. Groll, P. Munoz, and B.W. Teh. Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10). EClinicalMedicine. 2025.
Kinsella, P., K. Thursky, M.A. Slavin, and G.K. Reynolds. From guesswork to guidelines: advancing diagnostic stewardship in immunocompromised hosts. Expert Rev Anti Infect Ther. 2025.
Hill, J.A., J. Boonyaratanakornkit, M. Mikulska, B.W. Teh, W.O. Hahn, G. Haidar, C. Liu, D. Kumar, M.G. Ison, and N. Halasa. Innovation in active and passive immunisation of people who are immunocompromised: a call to action. Lancet Infect Dis. 2025.
Yong, M.K., K. Thursky, M. Crane, T. Spelman, R.K. Mahar, J.A. Simpson, A.M. Scott, S.J. Harrison, J. Szer, M. Pellegrini, S. Lingaratnam, K.C. Pang, S. Tennakoon, B.Z. Sim, E. Blyth, H.K. Gan, H. Quach, M.P. McIntosh, H. Page, R. Woolstencroft, and M. Slavin. Interferon-alpha Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. Clin Infect Dis. 2025.
Williams, L.J., C.S. Li-Wai-Suen, A.L. Garnham, S.M. Bader, C.S. Tam, A. Whitechurch, M.A. Slavin, M. Doerflinger, and B.W. Teh. Elucidating novel immune profiles for predicting infection in high-risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia. Clin Transl Immunology. 2025.
Westall, G.P., D. Gottlieb, P. Hughes, T. Marinelli, W.D. Rawlinson, D. Ritchie, J. Sasadeusz, and M.K. Yong. Emerging concepts of CMV in transplantation. Intern Med J. 2025.
Wang, X., C. Patel, M.L. Giles, P. Burns, K. Macartney, B. Teh, and P.C. Williams. Glucocorticoid Dosing and Implications for Vaccination: Evolution of Global Definitions. Clin Infect Dis. 2025.
Urbancic, K.F., D.C.M. Kong, P.D.R. Johnson, M.K. Yong, M.A. Slavin, and K. Thursky. Antifungal stewardship in Australian hospitals: defining the scope and future targets. Intern Med J. 2025.
Thorburn, S., S. Vogrin, S. Garner, O. Smibert, G. Reynolds, J. Kwong, J.A. Trubiano, and A.P. Douglas. Predictors of early line removal and successful line retention in potential central line-associated bloodstream infections in haematology patients: a retrospective cohort study. J Hosp Infect. 2025.
Stewart, A.G., K.B. Laupland, F. Edwards, M.A. Slavin, and S.C. Chen. Epidemiology, Significance and Clinical Outcomes of Bloodstream Infections Caused by Non-Candida and Non-Cryptococcus Yeasts. Mycoses. 2025.
Stewart, A.G., K.B. Laupland, F. Edwards, S. Koo, S.P. Hammond, P.N. Harris, D.L. Paterson, M.A. Slavin, and S.C. Chen. Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance. J Infect. 2025.
Stewart, A.G., K.B. Laupland, F. Edwards, I. Gassiep, S. Koo, S.P. Hammond, S.C. Chen, and M.A. Slavin. Clinical Characteristics and Outcomes in Patients With Cryptococcaemia From a Large Population-Based Cohort. Mycoses. 2025.
Smibert, O.C., S. Vogrin, M. Sinclair, A. Majumdar, M. Nasra, D. Pandey, H. Jahanabadi, J.A. Trubiano, K.A. Markey, M.A. Slavin, A. Testro, and J.C. Kwong. Antibiotic Exposure and Risk of Allograft Rejection and Survival After Liver Transplant: An Observational Cohort Study From a Tertiary Referral Centre. Transpl Infect Dis. 2025.
Roberts, J.A., F.B. Sime, J. Lipman, M.P. Hernández‑Mitre, J.P. Baptista, R.J. Bruggemann, J. Darvall, J.J. De Waele, G. Dimopoulos, J.Y. Lefrant, M.B. Mat Nor, J. Rello, L. Seoane, M.A. Slavin, M. Valkonen, M. Venditti, G. Ceccarelli, W.T. Wong, M. Zeitlinger, and C. Roger. Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units — the SAFE‑ICU study. Intensive Care Med. 2025.
Reynolds, G.K. & M.A. Slavin. The bottom line of CAR‑T fungal risk: low incidence, high stakes and the need for individualised antifungal prophylaxis. Transplant Cell Ther. 2025.
Puerta‑Alcalde, P., J. O’Keefe, R. Woolstencroft, S. Kaul, N. Lopez, K. Cronin, A. Lim, N. Garcia‑Pouton, M. Alvarez, L. Chee, M. Espasa, I. Grafia, M. Suarez‑Lledo, O. Smibert, C. Garcia‑Vidal, M.A. Slavin, M.K. Yong, A. Soriano, and L.J. Worth. Clostridioides difficile infection and recurrence in cancer patients (CIRCA): A multicentre, international study. Int J Infect Dis. 2025.
Ng, I., F. James, A. Copaescu, S. Vogrin, E. Mitri, M. Rose, R. Sullivan, M. Lane, A. Legg, J. Godsell, S. Fernando, L.H. Garvey, V. Sabato, P. Li, J.G. Peter, and J. Trubiano. Prolonged versus single dose in penicillin oral challenge testing: protocols for a pilot and definitive randomised controlled trial (PROSPECTOR studies). BMJ Open. 2025.
Marinelli, T., B. Teh, M. Giannella, M.G. Ison, M.B. Roberts, O. Bupha‑Intr, M. Slavin, & the Australasian Society for Infectious Diseases Immunocompromised Host Special Interest Group. Current Practice Patterns and Educational Needs of Immunocompromised Infectious Diseases Physicians in Australia and New Zealand. Transpl Infect Dis. 2025.
Maertens, J.A., G. Thompson, A. Spec, F.M. Donovan, S.P. Hammond, A.H.W. Bruns, G. Rahav, S. Shoham, R. Johnson, B.J. Rijnders, J.M. Schaenman, M. Hoenigl, C.O. Cornely, M.H. Miceli, C. Chen, T.J. White, C. Ross, M. Zinzi, J.H. Rex, M.A. Slavin, F. Fortún, N.H. Nguyen, T.F. Patterson, O. Uspenskaya, F.E.P. de Veerdonk, P.E. Verweij, A. Aoun, A. Georgala, B.D. Alexander, M. Chayakulkeeree, V. Mehra, M. Rautemaa‑Richardson, M. Moussa, R. Bazaz, S. Schwartz, J.H. Plate, D. Dane, and D. Trevino. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single‑arm, open‑label, phase 2b study. Med Mycol. 2025.
Liu, A.J., M.A. Slavin, S.J. Harrison, and B.W. Teh. Infections during novel myeloma therapies. Leuk Lymphoma. 2025.
Khawaja, F., D. Zamora, M.K. Yong, M. Hakki, B.K. Goscicki, L. Danziger‑Isakov, A. Lin, P.A. Carpenter, M. Boeckh, G.A. Papanicolaou, S.S. Dadwal, & R.F. Chemaly. American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients. Transplant Cell Ther. 2025.
Khanina, A., N. Singh, R. James, D.C.M. Kong, M.A. Slavin, & K.A. Thursky. Assessing the appropriateness of antifungal prescribing: key results from the implementation of a novel audit tool in Australian hospitals. J Antimicrob Chemother. 2025.
Hodges, M.R., M. Tawadrous, O.A. Cornely, G.R. Thompson III, M.A. Slavin, J.A. Maertens, S.S. Dadwal, G. Rahav, S. Hazel, M. Almas, A. Jakate, & R. Pypstra. Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by *Aspergillus* Species and Rare Molds: A Phase 2, Open‑Label Study (AEGIS). Clin Infect Dis. 2025.
Han, W., D. Martinez, V. Rozova, L. Cavedon, A. Khanina, L.J. Worth, M.A. Slavin, K.A. Thursky, & K. Verspoor. Automated Detection of Invasive Fungal Infections in Clinical Reports Using Medical Language Models. Stud Health Technol Inform. 2025.
Hall, V.G., O.C. Smibert, S.G. Sullivan, C. Lim, I.G. Barr, H. Peck, P. Fuge‑Larsen, J. Demajo, E. Klimevski, S. Tennakoon, N.R. Saunders, T. Joyce, A. Whitechurch, A. Khot, M.A. Anderson, J.A. Trubiano, M.K. Yong, L.J. Worth, T. Spelman, M.A. Slavin, & B.W. Teh. Influenza Vaccination Strategies in Patients with Hematologic Cancer. N Engl J Med. 2025.
Hall, V.G., T.H.O. Nguyen, O.C. Smibert, L.F. Allen, S.G. Sullivan, A. Fox, L. Carolan, A.K. Wheatley, S.J. Kent, B. Gilbertson, C. Lim, I.G. Barr, H. Peck, P. Fuge-Larsen, E. Klimevski, S. Tennakoon, N.R. Saunders, T. Joyce, A. Whitechurch, A. Khot, M.A. Anderson, J.A. Trubiano, L.J. Worth, M.K. Yong, M.A. Slavin, K. Kedzierska, & B.W. Teh. Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial. J Infect Dis. 2025.
Haidar, G., S. Thomas, P. Loubet, R.I. Baker, T. Benfield, J. Boonyaratanakornkit, S. Kiertiburanakul, A.H.J. Kim, E.E. Longbrake, J.M. Molina, R. Paredes, D. Tucker, A. Uriel, J. Weinmann-Menke, A.A. Aksyuk, L.E. Clegg, A. Currie, H. Yang, K. Flyrin, M. Gibbs, M. Shroff, J.L. Perez, L.J. Chang, T.S. Cohen, & S.S. Group. Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial. Lancet Infect Dis. 2025.
Giannella, M., D. Riccucci, R. Pascale, E. Cordero, N.J. Mueller, M. Slavin, M. Ison, E.S.G.O.I.F. Infection, & H. Infection in Immunocompromised. Current Practice Patterns and Educational Needs of the ESCMID Study Group for Infections in Compromised Hosts. Transpl Infect Dis. 2025.
Giannella, M., F. Lanternier, S. Delliere, A.H. Groll, N.J. Mueller, A. Alastruey‑Izquierdo, & M.A. Slavin; E.S.G.o.I.F. Infection & H. Infection in Immunocompromised. Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges. Clin Microbiol Infect. 2025.
Garg, P., N. Singh, A.J. Liu, M.K. Yong, M.A. Slavin, L. Hall, & L.J. Worth. Estimating the prevalence of key healthcare-associated and opportunistic infections in Australian transplant and cancer populations: protocol for the PROSPER point prevalence study. BMJ Open. 2025.
Douglas, A.P., E. Stohs, & M. Mikulska. The role of antibacterial prophylaxis in high-risk neutropenia: benefits, risks, and current perspectives. Curr Opin Infect Dis. 2025.
Coussement, J., C.H. Heath, M.B. Roberts, R.J. Lane, T. Spelman, O.C. Smibert, A. Longhitano, C.O. Morrissey, B. Nield, M. Tripathy, J.S. Davis, K.J. Kennedy, S.A. Lynar, L.C. Crawford, S.J. Crawford, B.J. Smith, A.P. Gador-Whyte, R. Haywood, A.A. Mahony, J.C. Howard, G.B. Walls, G.M. O'Kane, M.T. Broom, C.L. Keighley, O. Bupha-Intr, L. Cooley, J.A. O'Hern, J.D. Jackson, A.J. Morris, C. Bartolo, A.R. Tramontana, K.C. Grimwade, V. Au Yeung, R. Chean, E. Woolnough, B.W. Teh, M.A. Slavin, S.C.A. Chen, Australian & H.I.V.I. New Zealand Study Group for Cryptococcosis in Patients Without. Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New Zealand. Clin Infect Dis. 2025.
Chung, H., M. Krishnasamy, T. Joyce, T. Dryden, A. Whitechurch, P. Baden, S. Harrison, & B.W. Teh. "It's a risk-benefit analysis": Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia. Vaccine. 2025.
Bartoletti, M., O. Azap, A. Barac, M. Ben Selma, O. Ergonul, E. Gkrania-Klotsas, P.A. Grossi, R. Krause, B. Nagavci, J.R. Pano-Pardo, L.C. Pierrotti, N. Power, J. Rodriguez-Bano, M. Sibani, M.A. Slavin, B.G. Szabo, B. Tazza, N.N. Yung Tsang, S. Tsiodras, I. Zollner-Schwetz, R.F. Chemaly, E.S.G.f.I.i.C. Hosts, & E.S.G.f.R.V. the. Management of COVID-19 in immunocompromised patients: a European Society of Clinical Microbiology and Infectious Diseases consensus document. Clin Microbiol Infect. 2025.
